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37.2% for high cost-sharing; p0.001). CONCLUSIONS: Patients in plans with no
cost-sharing have greater adherence and are less likely to discontinue treatment in
the 12-month period following DMT initiation. These results suggest that patients
with MS are sensitive to the financial costs associated with DMT and may make
treatment decisions based on this burden. Manufacturer co-pay assistance pro-
grams designed to reduce patient financial burden were not considered in this
analysis. Therefore, these results may underestimate the effects of benefit design
on medication adherence and persistence.
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OBJECTIVES: Since launch, HTA agencies from Germany, France and UK have re-
peatedly reviewed the use of Alzheimer’s disease (AD) treatments and issued rec-
ommendations, which have changed over time. The aim of this study was to un-
derstand the drivers of agency decisions and whether these too have changed over
time. METHODS: We reviewed HTA appraisals by IQWIG, HAS and NICE for three
acetylcholinesterase inhibitors (AChEI) donepezil, galantamine, rivastigmine and
memantine, an NMDA receptor antagonist from marketing authorisation to today
and identified arguments leading to recommendations. RESULTS: Between 1997
and 2002, the EMA approved donepezil, rivastigmine and galantamine for mild to
moderate AD and memantine for moderate to severe AD. We identified 2 multiple
technology assessments (MTA) and 3 single technology assessments (STA) by
IQWIG, 1 MTA and 16 STAs from HAS and 3 MTAs from NICE. Germany: IQWIG
ascribed the AChEI class a modest clinical benefit. Following two negative assess-
ments of memantine, the decision was reversed based on post-hoc analysis of
initial registration studies. France: HAS initially assigned all treatments an impor-
tant clinical added value (AMSR II) acknowledging high innovation. Later HAS re-
viewed the compounds in a new comparative setting (after withdrawal of tacrine)
and assigned only a minor clinical added value (ASMR IV). UK: NICE recommended
AChEIs in 2001, restricted their use in 2006 and in 2011 again recommended them,
while memantine received two negative recommendations followed by a positive
recommendation. The last review was based on additional data from randomized
clinical trials and the Assessment Group’s model demonstrating delay to
institutionalisation. CONCLUSIONS: The agencies revised assessments based on
post-marketing data. Differing national approaches led to different decisions:
IQWIG emphasises patient relevant benefit, HAS the clinical added value versus
similar medicinal products and NICE cost-effectiveness. Although agency deci-
sions changed, decision drivers were consistent across evaluations.
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OBJECTIVES: To quantify annual drug costs and hospitalization rates (HR) of adult
refractory focal epilepsy patients in Germany. METHODS: We retrospectively esti-
mated the annual HR and medication for refractory focal epilepsy patients based
on the NeuroTransData epilepsy database (input from 79neurologists, 34centers,
1240patients). Inclusion criteria (at least 1year of disease history; documentation
and treatment period of at least 6months; treatment with at least 1anitepileptic
drug [AED] in patient history; at least 1seizure during 6months of monitoring) led to
the identification of 70 patients. Average ambulatory daily therapy costs among all
prescribed drugs included were based on public prices (2011) considering claw-
backs and average dosing (real world setting [RWS] vs. daily defined dosing [DDD]).
HR were based on number of patients hospitalized. RESULTS: On average 2.1AEDs
per patient were prescribed, mainly generic drugs or branded drugs close to loss of
patent protection. Average daily costs per prescribed drug ranged from 0.65€ (Val-
proate) to 9.51€ (Lacosamid). Daily drug costs per patient ranged between 7.01€
(RWS) and 6.16€ (DDD). Annual total drug costs per patient were on average
2,557.44€. An ambulatory consultation rate of 2.1visits per patient within 6months
was recorded. Average HR was 44%, taking into account various reasons: 56% emer-
gency, 20% new adjustment for medication, 18% documentation of seizure, 4%
rehabilitation, 2% pre-surgical diagnostics. Mean duration was 34.9 (CI: 20.2-49.6;
median 17.8) days per patient hospitalized. Due to the potential selection bias and
the low number of analysed patients these results must be seen as indicative.
CONCLUSIONS: A 44% HR and a high average number of inpatient days (1month)
within 1year point to an unmet need for treatment optimization in refractory focal
epilepsy patients. It indicates that patients receiving combination therapy of con-
ventional drugs are often not well controlled, supporting the consideration of using
more innovative drugs.
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OBJECTIVES: Several disease-modifying therapies (DMTs) including IFNB-1b have
been approved for patients with multiple sclerosis (MS) to delay disease progres-
sion and reduce the incidence of relapses. Fingolimod, the first oral formulation of
DMT, was recently approved in several nations around the world including Ger-
many. This study aims to conduct a cost-minimization analysis to estimate the
cost impact of MS treatment with Fingolimod versus INFB-1b in Germany from the
societal perspective.METHODS:A Markov model is developed to follow the natural
history MS patients from time of diagnosis through disease progression and up to
20 years. MS patients receive either IFNB-1b or Fingolimod treatment but share the
same efficacy on disease progression and relapse rate due to the absence of head-
to-head comparison data. Fingolimod patients are assumed to have 10% higher
treatment adherence due to the oral formulation. In the model, DMTs costs (IFNB-
1b: €19,444/year and Fingolimod: €30,584/year) are based on AVP pharmacy retail
price, while other cost items are estimated from published literatures or local
databases. Main model outcomes include direct costs, indirect costs, and total
costs. All costs are inflated to 2010 Euros and discounted annually at 5%. RESULTS:
In the short-term analysis, Fingolimod costs additional €8,929 per patient in one
year and €29,550 per patient in 5 years compared to IFNB-1b. Long-term analysis (20
years) shows that cost savings associated with IFNB-1b is €41,593 per patient,
which mainly occurs when MS patients are still receiving treatment. The cost
advantages of IFNB-1b in the long-term analysis are attributed to its lower drug cost
(€50,342 vs. €92,873), serious adverse events management (€6.7 vs. €102.4), and
clinical monitoring (€8.8 vs. €438.2). CONCLUSIONS: Compared to Fingolimod, MS
treatment with INFB-1b leads to substantial cost savings from both societal and
payer perspectives in Germany, with similar treatment effectiveness.
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OBJECTIVES: The SF-6D and the EQ-5D are two widely used questionnaires to
generate utility scores. The objective of this study is to describe and compare
utilities derived from EQ-5D and SF-6D in Huntington’s disease population.
METHODS:We used data from Euro-HDB, a multicenter cross-sectional study con-
ducted in France, Italy, Poland and Germany. In several subpopulations, with dif-
ferent degrees of severity, we used paired-samples t-test to identify significant
differences and calculated the Pearson’s correlation between SF-6D and the EQ-5D
utilities. RESULTS: The overall sample included 278 patients: 96 from France, 32
from Gemany, 103 from Italy and 47 from Poland. For the overall population, mean
utility scores were significantly different (EQ-5D: 0.34 (sd0.446); SF-6D: 0.62
(sd0.135); p0.0001). However values were strongly correlated (r 0.79, p0.001).
This difference was also significant when considering subpopulations (as discrim-
inated with score of clinical motor scale, and depression scale), with higher values
for SF-6D. The difference between EQ-5D and SF-6D utility scores was higher in
severe population than in moderate for most of the studied criteria (severe motor
impairment: EQ-5D: 0.62; SF-6D: 0.69; moderate motor impairment: EQ-5D: 0.00;
SF-6D: 0.51). The SF-6D scores distribution was found to be approximately normal
whereas the EQ-5D distribution was negatively skewed. CONCLUSIONS: In our
study, EQ-5D tends to generate lower scores in all Huntington’s disease subpopu-
lations. EQ-5D appears to be more sensitive than SF-6D. The choice of utility mea-
sure is likely to have a strong impact on incremental cost-effectiveness ratios of
interventions slowing the progression of Huntington’s disease.
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OBJECTIVES: The aim was to perform a cross-cultural adaptation and validation of
the Fatigue Severity Scale (FSS) for use in Brazilian patients with myopathy and
who complains of precocious muscular fatigue. METHODS: The FSS presents nine
items measured on a Likert scale ranging from 1 (completely disagree) to 7 (com-
pletely agree), where higher scores indicate higher level of fatigue. The process of
cross-cultural adaptation included: two independent translations for Portuguese
spoken in Brazil; the development of a consensual translated version; application
in a pilot group (n14) of patients with myopathy; evaluation by an expert com-
mittee for content validation; a back-translation by one bilingual translator whose
native tongue was English, but who was fluent in Brazilian Portuguese. The two
English versions (original and back translated) were analyzed by two of the authors
and a final Brazilian version was obtained. Twenty one patients with muscular
disease following at the outpatient clinic from a University Hospital answered the
Brazilian version of the FSS, the visual analogue scale (VAS) and the Chalder fatigue
questionnaire (CFQ). The following analyses were performed: exploratory factorial
analysis; internal consistency (Cronbach’s alpha); construct validity through of the
correlation with VAS and CFQ (physical and mental components). RESULTS: The
FSS scale obtained in the process of cross cultural adaptation was comprehensible
to individuals in the pilot population. The twenty one patients who participate in
the validation process were aged 21 to 65 years. The exploratory factor analysis
determined one factor, as the original version. Reliability analysis indicated satis-
factory internal consistency (0.93). Construct validity of the FSS (total score) with
VAS and CFQ demonstrated moderate correlations (0.60 and physical0.56, respec-
tively). The FSS didn=t correlate with mental component of the CFQ (0.31).
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CONCLUSIONS: The FSS scale is an instrument reliable and valid to measure mus-
cular fatigue in Brazilian patients with myopathy.
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IN AN OBSERVATIONAL STUDY OF CYSTIC FIBROSIS
Pasta DJ, Millar SJ, Rasouliyan L
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OBJECTIVES: To evaluate lung function decline before and after the initiation of
dornase alfa (DA) through a multivariable mixed-effects piecewise linear model
using data from the Epidemiologic Study of Cystic Fibrosis (ESCF). METHODS: Pa-
tients aged 8-38 years enrolled in ESCF for 2 or more years prior to initial treatment
with DA were selected if they remained on treatment for at least 2 years. A com-
parator group included cystic fibrosis patients not yet reported to have received DA.
FEV1 percent predicted (pp) was analyzed before and after an index measurement
within 30 days of either DA initiation (DA group) or an encounter within 1 year
following the 8th or subsequent even-numbered birthday (comparator group). For
each patient, we fit a regression line to FEV1 pp separately for the pre-index and
post-index periods (both 2 years in duration) using a mixed-effects piecewise linear
model adjusted for age, gender, pulmonary exacerbations, respiratory therapies,
and nutritional supplements. Patients were categorized by age group or by age-
adjusted deciles of the index FEV1 pp. RESULTS: The DA group (n2,230) had a
lower FEV1 pp at index and a more rapid decline during the pre-index period. There
was an acute improvement in FEV1 pp (change in intercept) associated with the
initiation of DA therapy. Furthermore, the mean rate of FEV1 pp decline was more
attenuated for the DA group than for the comparator group (n5,970) across age
groups and deciles. CONCLUSIONS: The use of DA for a 2-year period is associated
with both an acute improvement in FEV1 pp (previously shown in clinical trials)
and a reduction in the rate of FEV1 pp decline (shown for the first time). These
results demonstrate the value of using mixed-effects piecewise linear models in
observational studies to evaluate the effect of instituting a therapy on both the
slope and intercept of a continuous outcome.
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OBJECTIVES: The BURQOL-RD project is intended to develop a disease based model
capable of quantifying the socio-economic burden and Health-Related Quality of
Life (HRQOL) for patients with rare diseases (RD) and their caregivers in Europe. We
described the methodology used to select a set of 10 RD to be approached in a pilot
study. METHODS: BURQOL-RD project counts with 20 partners, from 8 European
countries: Spain, UK, France, Germany, Sweden, Italy, Hungary and Bulgaria. A
two-round Delphi process was used to generate consensus in the selection of the 10
RD among the project participants. The wide variability and dispersion of the re-
sponses received in the two Delphi rounds of prioritization suggested that an ad-
ditional procedure should be implemented to improve the representativeness of
selected diseases. A Lewis Carroll’s trilateral diagram was applied based on three
determinants. RESULTS: The two rounds of Delphi panel yielded into a prioritised
list, to which the Carroll diagram was applied, taking into account three determi-
nants: prevalence, availability of effective treatment and need for carer. The final
set of RD was obtained to be targeted in the pilot study of BURQOL-RD: Cystic
Fibrosis, Prader-Willi Syndrome, Haemophilia, Duchenne Muscular Dystrophy,
Epidermolysis Bullosa, Fragile X Syndrome, Sclerodermia, Mucopolysaccharidosis,
Juvenile Idiopathic Arthritis and Histiocytosis. CONCLUSIONS: This methodology
permitted to obtain an equilibrated set of RD for the pilot study of BURQOL-RD
project. The model that will be generated will not only be suitable to apply in a wide
range of RD but it will also be sufficiently flexible to identify and adapt to the
challenges faced by the different health and social care systems of EU member
states.
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BELATACEPT VERSUS TACROLIMUS: RESULTS OF AN INDIRECT ANALYSIS
FROM A SYSTEMATIC REVIEW OF IMMUNOSUPPRESSIVE THERAPIES FOR
KIDNEY TRANSPLANT RECIPIENTS
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OBJECTIVES: To systematically identify and summarise the evidence of renal
transplant outcomes, toxicity and adverse effects in order to determine the most
effective options. In particular, comparing tacrolimus, the cornerstone of renal
transplantation therapy, with newer therapies that have been introduced since
2003.METHODS:An electronic literature search of MEDLINE, Current Contents and
the Cochrane Library databases was conducted, plus manual reference checks of
all articles involving controlled trials of kidney transplants and immunosuppres-
sive therapy between 2003 and July 2010. Studies were assessed for eligibility and
quality by two reviewers who extracted data independently. Studies were classified
according to CNI avoidance or reduction, steroid avoidance, and induction thera-
pies. Results were expressed as risk ratio (RR) with 95% confidence intervals (CI).
Where necessary, indirect comparison techniques were used to compare different
forms of tacrolimus with belatacept. RESULTS: Thirty-five studies from an initial
list of 2895 citations were included in the analysis. Results show CNI avoidance
leads to higher incidence of acute rejection (RR 2.52, 95% CI 1.11–5.75), which is a
known predictor for graft loss, but reduced chronic allograft nephropathy. Tacroli-
mus produces better rejection prophylaxis compared with ciclosporin (RR 0.38, 95%
CI 0.21–0.70), and ciclosporin produces lower acute rejection compared with be-
latacept (RR 0.32, 95% CI 0.19–0.55). Indirect analysis shows that tacrolimus is
superior to belatacept in acute rejection prophylaxis (RR 0.18, 95% CI 0.08–0.39), but
leads to more cases of a decrease in glomerular filtration rate (GFR) (RR 1.37, 95% CI
0.92–2.03); however, the long-term impact of a reduction in GFR in the context of a
CNI-free regimen is not clear at present. CONCLUSIONS: Direct and indirect com-
parisons demonstrate that CNIs, and in particular tacrolimus, remain superior
even against more recent compounds for preventing acute rejection. However,
more research needs to be done to find the optimum combination of therapies.
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OBJECTIVES: To evaluate the comparative effectiveness of investigational com-
pound ferumoxytol for the treatment of iron deficiency anaemia (IDA) associated
with chronic kidney disease (CKD) compared to alternative iron replacement ther-
apies (IRT). Primary interest was the improvement in haemoglobin (Hb) from base-
line levels.METHODS:A comprehensive systematic review was conducted to iden-
tify any randomised controlled trials investigating the efficacy of IRTs for the
treatment of IDA in CKD where efficacy is defined as Hb change from baseline and
IRTs included intravenous (IV) and oral treatments. Twelve electronic databases
were searched up to November 2010 (language unrestricted). Two reviewers inde-
pendently assessed each identified reference and conducted subsequent data ex-
traction. Method quality of each included trial was also independently assessed in
accordance with NICE guidelines. A standard meta-analysis comparing oral iron to
ferumoxytol was initially conducted, reflecting the trial programme. The full net-
work of evidence that included IV and oral iron therapies was synthesised using a
mixed treatment comparison (MTC). The random effects model showed ‘predicting
superiority’ to the fixed effects model and was thus utilised. Mean efficacy was
estimated through analysing standardised effect sizes of trials and back-trans-
forming data to Hb values via weighted average standard deviation. RESULTS:
Seventeen published trials and one unpublished clinical study provided the heter-
ogeneous trial base for MTC analysis. Ferumoxytol was significantly favoured
when compared to oral iron therapy by conventional meta-analysis (0.61; 95%
CI0.44,0.79; P value0.0001) which was supported by results from the MTC ef-
ficacy analysis (0.48; 95% CI1.24,2.2). Significant differences in efficacy were not
observed between ferumoxytol and any of the alternative IV iron therapies.
CONCLUSIONS: The results from the conventional meta-analysis showed that the
model favoured investigational compound ferumoxytol, in terms of increasing Hb,
in comparison to oral iron therapy and suggested a modelled equivalence to cur-
rently approved alternative IV iron treatments.
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SOURCES OF HETEROGENEITY AMONG OVERACTIVE BLADDER CLINICAL TRIAL
ESTIMATES OF TOLTERODINE AND FESOTERODINE REDUCTIONS OF URGENCY
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OBJECTIVES: Explore potential sources of heterogeneity among estimates of tolt-
erodine (TOL) and fesoterodine (FESO) efficacy relative to placebo (PBO) in patients
with overactive bladder and urgency urinary incontinence (UUI) from randomized
clinical trials (RCTs) published from 2001 – 2010. METHODS: RCTs evaluating TOL
4mg, solifenacin 5mg and/or 10mg, or FESO 4mg or 8mg compared to PBO reporting
mean reduction of UUI episodes/d from baseline to endpoint were identified. Treat-
ment effects (treatment response minus PBO response) and PBO responses were
tested for heterogeneity using Cochran’s Q statistic. Where heterogeneity was
present, other study variables (baseline UUI, baseline micturitions, gender, age,
diary evaluation days, publication year, and study duration) were evaluated for
potential confounding using linear regression methods. RESULTS: Statistical het-
erogeneity was found among the 17 PBO responses (mean reduction of UUI) of the
included studies. PBO response increased with publication year, which accounted
for more than 27% of response variation. Publication year (p0.02), gender
(p0.003), and study duration (6-week vs. other) (p0.006) were significant predic-
tors of PBO response (adj. R20.6261). TOL and FESO 8mg treatment effect esti-
mates were also heterogeneous. Among the nine TOL trials, treatment responses
remained constant over publication year while PBO responses increased, resulting
in a net decline in TOL treatment effect (p0.0928). The majority of this decline was
explained by publication year and study duration (adj. R20.7703). The four FESO
8mg UUI responses also displayed a publication year-dependent decrease leading
to a decreasing treatment effect relative to PBO. However, this trend was almost
fully predictable by differential baseline UUI episodes (adj. R20.9721).
CONCLUSIONS: Publication year, gender, 6-week duration, and baseline UUI were
found to be significant predictors of PBO response or treatment effect. Additional
research should be done to understand why PBO response has increased over time
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